Anemia is chronically undermanaged in chronic kidney disease (CKD) patients and its etiology is poorly understood. Only 15% and 68% of CKD patients with anemia and severe anemia, respectively, received an official diagnosis; less than a quarter of diagnosed anemic patients and less than half of diagnosed severely anemic patients received treatment. The treatment goal of anemia is an increase in iron measures, yet safety concerns surround treatment options and leave guidelines nebulous. The benefits of options such as oral iron, intravenous iron, and erythropoiesis-stimulating agent (ESA) therapy must furthermore be balanced against significant adverse effects. A novel agent class known as hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) expands anemia treatment options for dialysis-dependent (DD) CKD patients; its optimization, however, is reliant on adequate knowledge. It is thus imperative that clinicians are appraised on this emerging agent class.
In the second activity of this CME Outfitters BriefCase series, expert faculty utilize case-based learning to utilize the latest data on novel therapies in clinical decision-making and guide learners through how best to address unmet needs in the treatment of anemia due to CKD.
- Provider:CME Outfitters, LLC
- Activity Link: https://www.cmeoutfitters.com/activity/challenges-in-anemia-in-ckd/
- Start Date: 2023-11-30 06:00:00
- End Date: 2023-11-30 06:00:00
- Credit Details: IPCE Credits: 0.5 hours
AAPA Category 1 Credit™️: 0.5 hours
AMA PRA Category 1 Credit™️: 0.5 hours
Nursing: 0.5 hours
Pharmacy: 0.5 hours - MOC Credit Details: ABIM - 0.5 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: Source: GlaxoSmithKline - Amount: 75666.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Internal Medicine